Reverse Transcriptase

Reverse transcriptases (RTs) are enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. Reverse transcriptases (RTs) use an RNA template and a short primer complementary to the 3' end of the RNA to direct the synthesis of the first strand cDNA.

Nucleoside reverse transcriptase inhibitors (NRTIs) block reverse transcriptase (an HIV enzyme). Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and block HIV reverse transcriptase. HIV uses reverse transcriptase to convert its RNA into DNA (reverse transcription). Blocking reverse transcriptase and reverse transcription prevents HIV from replicating.

Reverse Transcriptase Inhibitors

(Rac)-Efavirenz-d4

Cat. No.: HY-10572BS

(Rac)-Efavirenz-d4 ((Rac)-DMP 266-d4) is a labelled racemic Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

(Rac)-Tenofovir-d6

Cat. No.: HY-113904S

(Rac)-Tenofovir-d6 ((Rac)-GS 1278-d6) is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

2,2'-Anhydrouridine

(2,2'-Cyclouridine; O2,2'-Cyclouridine)

Cat. No.: HY-W012313

2,2'-Anhydrouridine is used for anticancer and antiviral research.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg

3'-Azido-3'-deoxy-5-methylcytidine

Cat. No.: HY-111640

3'-Azido-3'-deoxy-5-methylcytidine (CS-92) is a potent xenotropic murine leukemia-related retrovirus (**XMRV**) inhibitor with a CC_{50} of 43.5 μM in MCF-7 cells.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

4'-Ethynyl-2'-deoxyadenosine

Cat. No.: HY-125810

4'-Ethynyl-2'-deoxyadenosine (4'-E-dA), a nucleoside **reverse transcriptase (RT)** inhibitor, is an antiretroviral agent which is potent against drug-resistant HIV variants, with an EC_{50} of 98 nM in MT-4 cells for anti-HIV-1 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Abacavir

Cat. No.: HY-17423

Abacavir is a potent **nucleoside analog reverse-transcriptase inhibitor (NRTI)**.



Purity: 99.70%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Abacavir sulfate

(Abacavir Hemisulfate; ABC sulfate)

Cat. No.: HY-17423A

Abacavir sulfate (ABC) is a powerful nucleoside analog reverse transcriptase inhibitor (NRTI) used to treat HIV and AIDS.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Abacavir-d4

Cat. No.: HY-17423S

Abacavir-d4 is the deuterium labeled Abacavir. Abacavir is a potent **nucleoside analog reverse-transcriptase inhibitor (NRTI)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Adefovir

(GS-0393; PMEA)

Cat. No.: HY-B1826

Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**. Adefovir has an IC_{50} of 0.7 μM against **HBV** in the HepG2.2.15 cell line.



Purity: 99.74%
Clinical Data: Launched
Size: 10 mg, 25 mg, 50 mg, 100 mg

Adefovir dipivoxil

(GS 0840)

Cat. No.: HY-B0255

Adefovir dipivoxil, an adenosine analogue, is an oral prodrug of the **nucleoside reverse transcriptase** inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and **HBV** Lamivudine-resistant strains.



Purity: 99.99%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Adefovir-d4

(GS-0393-d4; PMEA-d4)

Cat. No.: HY-B1826S2

Adefovir-d4 (GS-0393-d4) is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 2.5 mg, 25 mg

Adefovir-d4 diphosphate triethylamine

Cat. No.: HY-B1826S1

Adefovir-d4 diphosphate triethylamine is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Adefovir-d4 phosphate triethylamine

Cat. No.: HY-B1826S

Adefovir-d4 phosphate triethylamine is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits **HBV DNA polymerase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

AG 555

(Tyrphostin AG 555)

Cat. No.: HY-15336

AG 555 (Tyrphostin AG 555), a potent antiretroviral drug, is a potent and selective inhibitor of **EGFR** and blocks **Cdk2** activation.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 100 mg, 250 mg

Alizarin complexone

Cat. No.: HY-121075

Alizarin complexone is a calcium-tracer and a chelating agent. Alizarin complexone is Rous-associated virus 2 reverse transcriptase (RAV-2 RT) inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AzddMeC

(CS-92)

Cat. No.: HY-105268

AzddMeC (CS-92) is an antiviral **nucleoside analogue** and a potent potent, selective and orally active **HIV-1 reverse transcriptase** and **HIV-1 replication** inhibitor. In **HIV-1**-infected human PBM cells and **HIV-1**-infected human macrophages, the EC_{50} values of AzddMeC are 9 nM and 6 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azvudine

(RO-0622; FNC)

Cat. No.: HY-19314

Azvudine (RO-0622) is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**. Azvudine exerts highly potent inhibition on HIV-1 (EC_{50}s ranging from 0.03 to 6.92 nM) and HIV-2 (EC_{50}s ranging from 0.018 to 0.025 nM).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Azvudine hydrochloride

(RO-0622 hydrochloride; FNC hydrochloride)

Cat. No.: HY-19314A

Azvudine (RO-0622) hydrochloride is a potent **nucleoside reverse transcriptase** inhibitor (NRTI), with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: ≥97.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BF738735

Cat. No.: HY-U00426

BF738735 is a phosphatidylinositol 4-kinase III beta (**PI4KIIIβ**) inhibitor with an IC_{50} of 5.7 nM.



Purity: 99.15%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg

Censavudine

(OBP-601; BMS-986001)

Cat. No.: HY-16776

Censavudine (OBP-601; BMS-986001), a **nucleoside analog**, is a **nucleoside reverse transcriptase** inhibitor. Censavudine is a potent **HIV** inhibitor with EC_{50} ranges from 30 nM to 81 nM and 450 nM to 890 nM for **HIV-2** and **HIV-1**, respectively.



Purity: 98.12%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Corilagin

Cat. No.: HY-N0462

Corilagin, a gallotannin, inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows good anti-tumor activity on hepatocellular carcinoma and ovarian cancer.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 20 mg

Corydine

Cat. No.: HY-N2571

Corydine is a naturally occurring alkaloid which can be extracted from plants such as Croton echinocarpus leaves. Corydine is efficient on inhibiting **reverse transcriptase** (RT) activity with an IC_{50} of 356.8 μg/mL.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

Daidzin

(Daidzoside; NPI-031D; Daidzein 7-O-glucoside)

Cat. No.: HY-N0018

Daidzin is an isoflavone that has anti-oxidant, anti-carcinogenic, and anti-atherosclerotic activities; directly inhibits mitochondrial aldehyde dehydrogenase 2 (IC50 = 80 nM) and is an effective anti-dipsotropic isoflavone.



Purity: 99.77%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dapivirine

(TMC120; R147681)

Cat. No.: HY-14266

Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and **nonnucleoside reverse transcriptase inhibitor (NRTI)**. Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase.



Purity: 99.90%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Dapivirine-d11

(TMC120-d11; R147681-d11)

Cat. No.: HY-14266S

Dapivirine-d11 (TMC120-d11) is the deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and **nonnucleoside reverse transcriptase inhibitor (NRTI)**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Delavirdine

(U 90152; BHAP-U 90152)

Cat. No.: HY-10571

Delavirdine (U 90152) is a potent, highly specific and orally active **non-nucleoside reverse transcriptase** inhibitor (NNRTI).



Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 25 mg

Delavirdine mesylate

(U 90152 mesylate; BHAP-U 90152 mesylate)

Cat. No.: HY-10571A

Delavirdine (U 90152) mesylate is a potent, highly specific and orally active **non-nucleoside reverse transcriptase** inhibitor (NNRTI).



Purity: 99.33%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Dexelvucitabine

(Reverset; d-d4FC)

Cat. No.: HY-14920

Dexelvucitabine (Reverset; d-d4FC), a Cytidine (HY-B0158) analog, is an orally active **nucleoside reverse transcriptase** inhibitor. Dexelvucitabine is a powerful drug against **HIV-1-resistant viruses** containing a thymidine analog and/or M184V mutation in the viral polymerase.



Purity: 99.52%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Didanosine

(2',3'-Dideoxyinosine; ddI)

Cat. No.: HY-B0249

Didanosine(Videx) is a reverse transcriptase inhibitor with an IC50 of 0.49 μM. Target: NRTIs; HIV Didanosine is a dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen.



Purity: 99.75%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Didanosine-d2

Cat. No.: HY-B0249S

Didanosine-d2 is the deuterium labeled Didanosine. Didanosine (Videx) is a reverse transcriptase inhibitor with an IC_{50} of 0.49 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Doravirine

(MK-1439) Cat. No.: HY-16767

Doravirine (MK-1439) is a highly specific **HIV-1 nonnucleoside reverse transcriptase** inhibitor with IC_{50}s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and **K103N** and **Y181C reverse transcriptase** mutants, respectively.



Purity: ≥98.0%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Efavirenz

(DMP 266; EFV; L-743726) Cat. No.: HY-10572

Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Efavirenz-d5

Cat. No.: HY-10572S

Efavirenz-d5 (DMP 266-d5) is the deuterium labeled Efavirenz. Efavirenz (DMP 266) is a potent inhibitor of the wild-type **HIV-1 reverse transcriptase** with a K_i of 2.93 nM and exhibits an IC_{95} of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture.



Purity: >98%
Clinical Data:
Size: 500 µg, 5 mg

EFdA-TP

Cat. No.: HY-138561

EFdA-TP is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP inhibits **HIV-1** RT with multiple mechanisms.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

EFdA-TP tetraammonium

Cat. No.: HY-138561A

EFdA-TP tetraammonium is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP tetraammonium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetraammonium inhibits **HIV-1** RT with multiple mechanisms.



Purity: 98.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

EFdA-TP tetrasodium

Cat. No.: HY-138561B

EFdA-TP tetrasodium is a potent **nucleoside reverse transcriptase (RT)** inhibitor. EFdA-TP tetrasodium inhibits RT-catalyzed DNA synthesis as an effective immediate or delayed chain terminator (ICT or DCT). EFdA-TP tetrasodium inhibits **HIV-1** RT with multiple mechanisms.



Purity: 95.18%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emtricitabine

(BW1592) Cat. No.: HY-17427

Emtricitabine is a nucleoside reverse transcriptase inhibitor (**NRTI**) with an EC_{50} of 0.01 µM in PBMC cell. It is an antiviral drug for the treatment of **HIV** infection.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg, 500 mg

Emtricitabine S-oxide

(Emtricitabine sulfoxide; Emtricitabine Degradant-III) Cat. No.: HY-100096

Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Emtricitabine-15N,D2

(BW1592-15N,D2) Cat. No.: HY-17427S

Emtricitabine-15N,D2 (BW1592-15N,D2) is a 15N-labeled and deuterium labeled Emtricitabine. Emtricitabine is a nucleoside reverse transcriptase inhibitor (**NRTI**) with an EC_{50} of 0.01 µM in PBMC cell. It is an antiviral drug for the treatment of **HIV** infection.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etravirine

(R165335; TMC125) Cat. No.: HY-90005

Etravirine is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: 99.56%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Etravirine D4

(TMC-125 D4; R-165335 D4)

Cat. No.: HY-90005S

Etravirine D4 (TMC-125 D4) is the deuterium labeled Etravirine. Etravirine is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Etravirine-d8

Cat. No.: HY-132508S

Etravirine-d8 (R165335-d8) is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**) used for the treatment of HIV.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

FNC-TP

Cat. No.: HY-139262

FNC-TP is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: 99.92%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

FNC-TP trisodium

Cat. No.: HY-139262A

FNC-TP trisodium is the intracellular active form of FNC. FNC is a potent **nucleoside reverse transcriptase inhibitor (NRTI)**, with antiviral activity on **HIV**, **HBV** and **HCV**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gramine

(Donaxine)

Cat. No.: HY-N0166

Gramine (Donaxine) is a natural alkaloid isolated from giant reed, acts as an active **adiponectin receptor (AdipoR)** agonist, with **IC_{50}**s of 3.2 and 4.2 μM for AdipoR2 and AdipoR1, respectively. Gramine is also a human and mouse **β2-Adrenergic receptor (β2-AR)** agonist.



Purity: 99.63%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 50 mg

IQP-0528

Cat. No.: HY-19509

IQP-0528 is a highly potent **nonnucleoside reverse transcriptase inhibitor** (NNRTI). IQP-0528 shows nanomolar activity against both HIV-1 and HIV-2, with an HIV-1 EC_{50} of 0.2 nM and an HIV-2 EC_{50} of 100 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Islatravir

(MK-8591)

Cat. No.: HY-104012

Islatravir (MK-8591) is a potent anti-**HIV-1** agent, acting as a nucleoside **reverse transcriptase** inhibitor, with **EC_{50}**s of 0.068 nM, 3.1 nM and 0.15 nM for HIV-1 (WT), HIV-1 (M184V), HIV-1 (MDR), respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lamivudine

(BCH-189)

Cat. No.: HY-B0250

Lamivudine (BCH-189) is a **nucleoside reverse transcriptase inhibitors (NRTIs)**. Lamivudine (BCH-189) can inhibit **HIV reverse transcriptase 1/2** and also the reverse transcriptase of **hepatitis B virus**.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Lamivudine 13C,15N2

Cat. No.: HY-135330

Lamivudine 13C,15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Lersivirine

(UK-453061)

Cat. No.: HY-14267

Lersivirine (UK-453061) is potent and selective **non-nucleoside reverse transcription** inhibitor (NNRTI; **IC_{50}**=119 nM) with excellent efficacy against NNRTI-resistant viruses.



Purity: 98.33%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Loviride

(R 89439)

Cat. No.: HY-15355

Loviride (R 89439) is a non-nucleoside reverse transcriptase inhibitor (**NNRTI**), with an IC_{50} of 0.3 μM for **reverse transcriptase** from **HIV-1**. Loviride (R 89439) inhibits HIV-1, HIV-2 and SIV replication in MT-4 cells.



Purity: 99.83%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Nevirapine

(BI-RG 587; NSC 641530; NVP)

Cat. No.: HY-10570

Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: 99.01%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Nevirapine-d3

Cat. No.: HY-10570S1

Nevirapine-d3 (BI-RG 587-d3) is the deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: >98%
Clinical Data:
Size: 2.5 mg, 25 mg

Nevirapine-D4

Cat. No.: HY-10570S

Nevirapine-D4 is deuterium labeled Nevirapine. Nevirapine is a non-nucleoside inhibitor of **HIV-1** reverse transcriptase used to treat and prevent HIV/AIDS; with a K_i of 270 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Nigranoic acid

Cat. No.: HY-122935

Nigranoic acid is a triterpenoid separated from Schisandra chinensis. Nigranoic acid inhibits **HIV-1 reverse transcriptase**. Nigranoic acid exhibits protective effects on brain through PARP/AIF signaling pathway in cerebral ischemia-reperfusion animal model.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Pyridoxal phosphate

(Pyridoxal 5′-phosphate; Pyridoxyl phosphate)

Cat. No.: HY-B1744

Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of **reverse transcriptases**, and is used for the treatment of tardive dyskinesia.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 1 g

Pyridoxal phosphate-d5

Cat. No.: HY-B1744S

Pyridoxal phosphate-d5 (Pyridoxal 5′-phosphate-d5) is the deuterium labeled Pyridoxal phosphate. Pyridoxal phosphate is the active form of vitamin B6, acts as an inhibitor of **reverse transcriptases**, and is used for the treatment of tardive dyskinesia.



Purity: >98%
Clinical Data:
Size: 500 μg, 5 mg

R-10015

Cat. No.: HY-120097

R-10015, a broad-spectrum antiviral compound for HIV infection, acts as a potent and selective inhibitor of **LIM domain kinase (LIMK)** and binds to the ATP-binding pocket, with an IC_{50} of 38 nM for human LIMK1.



Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Rilpivirine

(R278474; TMC278; DB08864)

Cat. No.: HY-10574

Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside **reverse transcriptase** inhibitor (**NNRTI**). Rilpivirine has high antiviral activity against wild-type **HIV** (EC_{50}=0.4 nM) and mutant viruses (EC_{50}=0.1-2.0 nM).



Purity: 98.61%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg

Rilpivirine-d6

Cat. No.: HY-10574S

Rilpivirine-d6 is the deuterium labeled Rilpivirine. Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside **reverse transcriptase** inhibitor (**NNRTI**).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 10 mg

Ro-0335

Cat. No.: HY-13053

RO-0335 is a novel and potent diphenylether **nonnucleoside reverse transcriptase inhibitor(NNRTI)**. RO-0335 inhibits **Wt HIV-1** with an IC_{50} of 1.1 nM and retained activity (IC_{50}< 100 nM) against 92% of a large number of NNRTI-resistant clinical isolates.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Rovafovir etalafenamide

(GS-9131)

Cat. No.: HY-19851

Rovafovir etalafenamide (GS-9131), a prodrug of the adenosine nucleotide analogue GS-9148, is an orally active nucleoside reverse transcriptase inhibitor **(NRTI)**. Rovafovir etalafenamide is potent and active against a variety of NRTI mutants, and shows potent anti-HIV-1 activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SPK-601

(LMV-601)

Cat. No.: HY-70083

SPK-601 (LMV-601) is an inhibitor of the **phosphatidylcholine-specific phospholipase C (PC-PLC)**. SPK-601 also can be used as an antimicrobial agent.



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg

Stampidine

Cat. No.: HY-122470

Stampidine is a **nucleoside reverse transcriptase inhibitor (NRTI)** with potent and broad-spectrum anti-HIV activity. Stampidine inhibits the laboratory HIV-1 strain $HTLV_{IIIB}$ (B-envelope subtype) and primary clinical isolates with **IC_{50}**s of 1 nM and 2 nM, respectively.



Purity: 99.80%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Stavudine

(d4T)

Cat. No.: HY-B0116

Stavudine (d4T) is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine has activity against **HIV-1** and **HIV-2**. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: 99.67%
Clinical Data: Launched
Size: 10 mM × 1 mL, 100 mg, 500 mg

Stavudine sodium

(d4T sodium)

Cat. No.: HY-B0116A

Stavudine (d4T) sodium is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine sodium has activity against **HIV-1** and **HIV-2**. Stavudine sodium also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Stavudine-d4

Cat. No.: HY-B0116S

Stavudine-d4 is the deuterium labeled Stavudine. Stavudine (d4T) is an orally active **nucleoside reverse transcriptase** inhibitor **(NRTI)**. Stavudine has activity against **HIV-1** and **HIV-2**. Stavudine also inhibits the replication of mitochondrial DNA (mtDNA).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Suramin

Cat. No.: HY-B0879

Suramin is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin is a potent inhibitor of **sirtuins**: SirT1 (**IC_{50}**=297 nM), SirT2 (**IC_{50}**=1.15 μM), and SirT5 (**IC_{50}**=22 μM).

Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Suramin sodium salt

(Suramin hexasodium salt)

Cat. No.: HY-B0879A

Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive **protein-tyrosine phosphatases (PTPases)** inhibitor. Suramin sodium salt is a potent inhibitor of **sirtuins**: SirT1 (**IC_{50}**=297 nM), SirT2 (**IC_{50}**=1.15 μM), and SirT5 (**IC_{50}**=22 μM).

Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg

Tenofovir

(GS 1278; PMPA)

Cat. No.: HY-13910

Tenofovir (GS 1278) is a **nucleotide reverse transcriptase** inhibitor to treat **HIV** and chronic Hepatitis B (**HBV**).



Purity: 99.81%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide

(GS-7340) Cat. No.: HY-15232

Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.92%
Clinical Data: Phase 4
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide fumarate

(GS-7340 (fumarate)) Cat. No.: HY-15232A

Tenofovir alafenamide fumarate (GS-7340 fumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide hemifumarate

(GS-7340 hemifumarate) Cat. No.: HY-15232B

Tenofovir alafenamide hemifumarate (GS-7340 hemifumarate) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: 99.45%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tenofovir alafenamide-d7

(GS-7340-d7) Cat. No.: HY-15232S

Tenofovir alafenamide-d7 (GS-7340-d7) is the deuterium labeled Tenofovir alafenamide. Tenofovir alafenamide (GS-7340) is an investigational oral prodrug of Tenofovir. Tenofovir is a **HIV-1** nucleotide reverse transcriptase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tenofovir diphosphate

(TFV-DP) Cat. No.: HY-136548

Tenofovir diphosphate (TFV-DP) is a competitive **DNA polymerases** inhibitor (with respect to dATP) and a substrate of HIV type 1 (**HIV-1**) **reverse transcriptase** (RT).



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Tenofovir diphosphate triethylamine

(TFV-DP triethylamine) Cat. No.: HY-136548A

Tenofovir diphosphate triethylamine (TFV-DP triethylamine) is a competitive **DNA polymerases** inhibitor (with respect to dATP) and a substrate of HIV type 1 (**HIV-1**) **reverse transcriptase** (RT).



Purity: 94.93%
Clinical Data: No Development Reported
Size: 1 mg

Tenofovir Disoproxil

(Bis(POC)-PMPA; GS 4331) Cat. No.: HY-13782A

Tenofovir Disoproxil (Bis(POC)-PMPA) is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: 99.72%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir Disoproxil fumarate

(Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate) Cat. No.: HY-13782

Tenofovir Disoproxil fumarate is a **nucleotide reverse transcriptase** inhibitor used to treat **HIV** and chronic **Hepatitis B**.



Purity: 99.50%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Tenofovir hydrate

(GS 1278 hydrate; PMPA hydrate) Cat. No.: HY-13910A

Tenofovir hydrate is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: ≥98.0%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tenofovir maleate

(GS 1278 maleate; PMPA maleate) Cat. No.: HY-13910B

Tenofovir Disoproxil Fumarate is a **nucleotide reverse transcriptase inhibitor** to treat HIV and chronic Hepatitis B.



Purity: >98%
Clinical Data: Launched
Size: 1 mg, 5 mg

Zalcitabine

(2',3'-Dideoxycytidine; ddC; Dideoxycytidine) **Cat. No.:** HY-17392

Zalcitabine is a potent nucleoside analogue reverse transcriptase inhibitor used in the treatment of **HIV** infection.



Purity: 99.81%
Clinical Data: Launched
Size: 10 mM × 1 mL, 50 mg, 100 mg

β-Rubromycin

Cat. No.: HY-122482

β-Rubromycin is a potent and selective inhibitor of human immunodeficiency virus-1 (HIV-1) RNA-directed DNA polymeras (**reverse transcriptase**). β-Rubromycin is a class of quinone antibacterials.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg